Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GSK5458514 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on GSK5458514, a putative T-cell engager targeting PSMA (Jul 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GSK5458514 | GSK 5458514|GSK-5458514 | PSMA Antibody 22 | Limited information is currently available on GSK5458514, a putative T-cell engager targeting PSMA (Jul 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06990880 | Phase Ib/II | GSK5458514 | A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer | Recruiting | USA | CAN | 1 |